Pharmacia & Upjohn Aktiebolag

Metcon Medicin Ab

Pharmacia Ab

Esperion Therapeutics, Inc.

Mats Lake

Erik Holmgren

Henri Hansson

Cesare Sirtori

Peter Lind

Joanna Chmielewska

Kerstin Hansson

Guido Franceschini

Lars B Abrahmsen

Bj&ouml;rn M Nilsson

Bjorn Nilsson

Lars Abrahms&eacute;n

Torsten Sejlitz

ANGsa Mikaelsson

Christina Kalderen

Lars Abrahamsen

Dysglucaemia is treated and/or prevented by the administration of granulated starch, enzymatically degraded and releasing reducing sugars at a rate, adjusted to the metabolism of the patient, suffering from dysglucaemia. For example nocturnal hypoglycaemia in diabetic patients is prevented by administering to said patients a granulate or tablets comprising granulated cornstarch, and preferably also heat treated cornstarch and a low calorie sweetener. The inventive granulation minimizes the available surface area and retards the enzymatic degradation of the cornstarch and ensures a controlled, e.g. a substantially linear release of reducing sugars, such as glucose, and a stable blood glucose level during several hours. The granulate or tablets are low in calories and contain no free sugar.

Composition and method for the treatment of dysglucaemia

Dysglucaemia is treated and/or prevented by the administration of granulated starch, enzymatically degraded and releasing reducing sugars at a rate, adjusted to the metabolism of the patient, suffering from dysglucaemia. For example nocturnal hypoglycaemia in diabetic patients is prevented by administering to said patients a granulate or tablets comprising granulated cornstarch, and preferably also heat treated cornstarch and a low calorie sweetener. The inventive granulation minimises the available surface area and retards the enzymatic degradation of the cornstarch and ensures a controlled, e.g. a substantially linear release of reducing sugars, such as glucose, and a stable blood glucose level during several hours. The granulate or tablets are low in calories and contain no free sugar.

Substantially pure dimers of Apolipoprotein AI-Milano (APO-AI-M/APO AI-M) were isolated from plasma and characterized. Apolipoprotein AI-M dimer can also be produced in a recombinant system. Pharmaceutical compositions comprising the ApoAI-AI-M/ApoAI-M are described. Patients with atherosclerosis or cardiovascular diseases can be treated with the dimer. Medicaments containing the dimer can also be used to prevent thrombosis in different clinical circumstances, both at the arterial and at the venous level. The dimer can also act as a prodrug for the monomer.

Dimer of molecular variant of apolipoprotein and processes for the production thereof

Dimer of molecular variant of apolipoprotein and processes for the

Expression system for producing apolipoprotein AI-M

Medicinal use of IFG-II

Growing community of inventors

Lidingo, Sweden

Mats Lake